Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study

European Journal of Heart Failure

Volumn 21, Issue 5, 2019, Pages 676-684

  Bavendiek, Udo ^a,e   Berliner, Dominik ^a   Dávila, Lukas Aguirre ^a,e   Schwab, Johannes ^b   Maier, Lars ^c   Philipp, Sebastian A ^d   Rieth, Andreas ^e   Westenfeld, Ralf ^f   Piorkowski, Christopher ^g   Weber, Kristina ^a,e   Hänselmann, Anja ^a   Oldhafer, Maximiliane ^a   Schallhorn, Sven ^a   von der Leyen, Heiko ^e,h   Schröder, Christoph ^a   Veltmann, Christian ^a,e   Störk, Stefan ^e,i   Böhm, Michael ^e,j   Koch, Armin ^a,e   Bauersachs, Johann ^a,e   Tebbe, Ulrich ^e   von Haehling, Stephan ^e   Haass, Markus ^e   Anker, Stefan ^e   Mohacsi, Paul ^e   Pölzl, Gerhard ^e   Trampisch, Helmut ^e   Zimmermann, Silke ^e   Neuhaus, Barbara ^e   more..

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Paracelsus Medical University   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d Elbe Klinikum Stade   (Germany)

^e Rheuma and Thoracic Center ^*

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^h Hannover Clinical Trial Center   (Germany)

ⁱ UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^j SAARLAND UNIVERSITY   (Germany)

more..

Author keywords

Cardiac glycosides; Clinical trial; Digitalis; Digitoxin; Heart failure

Indexed keywords

CARDIAC GLYCOSIDE; DIGITOXIN; PLACEBO; CARDIOTONIC AGENT;

ADULT; ALL CAUSE MORTALITY; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEW YORK HEART ASSOCIATION CLASS; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX; TREATMENT OUTCOME; YOUNG ADULT; CAUSE OF DEATH; CHRONIC DISEASE; CLINICAL TRIAL; HOSPITALIZATION; MORTALITY; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL;

CARDIOTONIC AGENTS; CAUSE OF DEATH; CHRONIC DISEASE; DIGITOXIN; DOUBLE-BLIND METHOD; HEART FAILURE; HOSPITALIZATION; HUMANS; MORTALITY;

EID: 85065499286     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.1452     Document Type: Article

References (36)

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
2. Christ M, Stork S, Dorr M, Heppner HJ, Muller C, Wachter R, Riemer U; Trend HF Germany Project. Heart failure epidemiology 2000-2013: insights from the German Federal Health Monitoring System. Eur J Heart Fail 2016;18:1009–1018.
3. Neumann T, Biermann J, Erbel R, Neumann A, Wasem J, Ertl G, Dietz R. Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives. Dtsch Arztebl Int 2009;106:269–275.
4. Guha K, McDonagh T. Heart failure epidemiology: European perspective. Curr Cardiol Rev 2013;9:123–127.
5. Jhund PS, Macintyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, Chalmers JW, Capewell S, McMurray JJ. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009;119:515–523.
6. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–533.
7. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993;22:955–962.
8. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, Smith LK, Van Voorhees L, Gourley LA, Jolly MK. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993;329:1–7.
9. Young JB, Gheorghiade M, Uretsky BF, Patterson JH, Adams KF Jr. Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme. J Am Coll Cardiol 1998;32:686–692.
10. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871–878.
11. Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS, Adams KF, Gheorghiade M. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006;27:178–186.
12. Ahmed A, Pitt B, Rahimtoola SH, Waagstein F, White M, Love TE, Braunwald E. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol 2008;123:138–146.
13. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–2962.
14. Cox JL, Ramer SA, Lee DS, Humphries K, Pilote L, Svenson L, Tu JV. Pharmacological treatment of congestive heart failure in Canada: a description of care in five provinces. Can J Cardiol 2005;21:337–343.
15. Patel N, Ju C, Macon C, Thadani U, Schulte PJ, Hernandez AF, Bhatt DL, Butler J, Yancy CW, Fonarow GC. Temporal trends of digoxin use in patients hospitalized with heart failure: analysis from the American Heart Association Get With the Guidelines-Heart Failure Registry. JACC Heart Fail 2016;4:348–356.
16. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA, Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1574–1585.
17. Belz GG, Breithaupt-Grogler K, Osowski U. Treatment of congestive heart failure – current status of use of digitoxin. Eur J Clin Invest 2001;31:10–17.
18. Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, Steeds RP, Townend J, Kotecha D. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015;351:h4451.
19. Bavendiek U, Aguirre Davila L, Koch A, Bauersachs J. Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. Eur Heart J 2017;38:2095–2099.
20. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Control Clin Trials 1984;5:348–361.
21. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875–885.
22. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.
23. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429–1435.
24. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN; SOLV Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293–302.
25. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001–2007.
26. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W; MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329–1338.
27. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–717.
28. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21.
29. Castagno D, Petrie MC, Claggett B, McMurray J. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J 2012;33:1137–1141.
30. Rush CJ, Campbell RT, Jhund PS, Petrie MC, McMurray JJ. Association is not causation: treatment effects cannot be estimated from observational data in heart failure. Eur Heart J 2018;39:3417–3438.
31. Staiger J, Spath J, Dickhuth HH, Keul J. Ventricle function in low-dose digitoxin in patients with chronic heart failure (stage II/III). Z Kardiol 1983;72:448–455.
32. Storstein L. Studies on digitalis. XI. Digitoxin metabolism in patients with impaired renal function. Clin Pharmacol Ther 1977;21:536–546.
33. Belz GG, Erbel R, Schumann K, Gilfrich HJ. Dose-response relationships and plasma concentrations of digitalis glycosides in man. Eur J Clin Pharmacol 1978;13:103–111.
34. Jagielska J, Salguero G, Schieffer B, Bavendiek U. Digitoxin elicits anti-inflammatory and vasoprotective properties in endothelial cells: therapeutic implications for the treatment of atherosclerosis? Atherosclerosis 2009;206:390–396.
35. Bauersachs J, Widder JD. Endothelial dysfunction in heart failure. Pharmacol Rep 2008;60:119–126.
36. Bavendiek U, Aguirre Davila L, Schwab J, Phillip SA, Westenfeld R, Maier LS, Stoerk S, Weber K, Koch A, Bauersachs J; DIGIT-HF Study Group. Digitoxin serum concentrations affecting patient safety and potential outcome in patients with HFrEF – analyses of the ongoing DIGIT-HF-trial. Eur Heart J 2017;38(Suppl 1): P6168 (abstr).